Skip to content

Repligen

US · RGEN #1445 by market cap Listed 1970
163.81 -6.48 -3.81%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 170.59 +0.18%
After-hours 163.81 0.00%
194.57113.17163.812026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RGEN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -1.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 11.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall C-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 155.0x Better than 2%
Price / Sales 13.3x Better than 8%
Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -2.7% Better than 16%
Net income CAGR (3Y) -35.9% Better than 9%
Free cash flow CAGR (3Y) 33.3% Better than 76%
Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 52.3% Better than 65%
Operating margin 5.6% Better than 37%
Net margin 6.6% Better than 49%
Return on equity 2.4% Better than 31%
Return on invested capital 2.4% Better than 35%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -9.6% Better than 52%
6-month return 42.4% Better than 94%
12-month return (ex latest month) 8.9% Better than 45%
Distance below 52-week high 17.6% Better than 66%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 8.4x Better than 92%
Debt to assets 23.4% Better than 51%
Interest coverage 3.9x Better than 50%
Free cash flow / net income 187.5% Better than 74%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 87.5% Better than 69%
Upside to average target 28.4% Better than 46%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.37%
1M -8.42%
3M -9.14%
6M +46.60%
YTD -0.03%
1Y +6.12%
3Y +5.25%
5Y -42.50%

Key statistics

Price & volume

Prev close
170.29
Open
169.61
Day range
162.47 - 169.61
Avg price
165.31
Volume
697.70K
Turnover
115.34M
Amplitude
4.20%
52-week range
100.99 - 198.87

Valuation

P/E
190.48
P/E (TTM)
-780.05
P/B
5.01
EPS
0.86
Net profit
54.97M
Net assets
2.09B

Share structure

Market cap
10.47B
Float cap
9.99B
Shares out
63.92M
Float shares
60.96M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 64% of range
100.99 198.87

17.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+20.08M net over the window

Short interest

Shares short
7.05M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Repligen (RGEN)?

Repligen last traded at 163.81. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Repligen's market cap?

About 10.47B.

What is the P/E ratio of Repligen?

The trailing twelve-month P/E is -780.05, below its own 5-year average of 111.31 — toward the bottom of its historical range (12.20% percentile). See the Valuation tab for the full history.

Does Repligen pay a dividend?

Repligen does not currently pay a regular dividend.

Is Repligen a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 210.29, which implies 28.4% upside from the current price. This is not investment advice.

What is Repligen's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Repligen a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Repligen discussion 0 comments

Add a comment